Insmed, Inc. is a pharmaceutical company based in the United States that focuses on improving the lives of patients with serious and rare diseases. Their flagship product, ARIKAYCE, is approved in the US for treating Mycobacterium Avium Complex (MAC) lung disease. With an ESG score of 25.7, Insmed is considered a medium risk company. In addition to ARIKAYCE, the company is also developing innovative treatments such as Brensocatib and INS1009 for various inflammatory and pulmonary diseases.